Empowering Early-Career Scientists: Jennifer Hawkins’ Journey at the REID Bioanalytical Forum

At Resolian, we believe science thrives when passionate minds are given the chance to grow.

That’s why we were thrilled to see one of our own, Jennifer Hawkins, selected as a bursary winner for the 50th International Reid Bioanalytical Forum (8 – 11 September 2025).

Jennifer’s story is one of curiosity, commitment, and continuous learning. As a Bioanalytical Scientist in our LCMS department for the past three years, she has focused on developing and validating small molecule assays using LC-MS/MS – work that supports both clinical and pre-clinical studies and ultimately helps progress therapies for a wide range of illnesses.

“Within my role I focus on the development and validation of small molecule assays for analysis by LC-MS/MS. My work supports sample analysis from both clinical and pre-clinical studies, progressing the development of therapies for a wide range of illnesses.”

When asked about her next steps, Jennifer shared:
“I see myself stepping into a method development role more heavily and improving my technical knowledge.”

The REID bursary has been a catalyst for that journey, enabling her to present her investigation into conflicting stability data to an international audience.

Why do bursaries matter? Jennifer explains:
“They allow early-career professionals like myself to attend development opportunities we might not otherwise access. By removing cost barriers, these programs open doors to networking and technical growth.”

Her advice to the bioanalytical community is clear:
“Provide as many opportunities as possible – whether through presentations, collaborations, or training. Experience is the greatest teacher.”

At Resolian, we’re proud to support scientists like Jennifer who are shaping the future of bioanalysis.

Because when talent meets opportunity, innovation thrives.

Jennifer Hawkins

Bioanalytical Scientist

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.